Category Archives: Inside BIO Industry Analysis

BIO’s Dave Thomas Talks VC Funding with Daniel Levine

72263479

Last week, BIO Industry Analysis’s Dave Thomas spoke with Daniel Levine for his weekly podcast, The Bio Report. Dave discussed BIO‘s Venture Funding of Therapeutic Innovation Report, of which he is the lead author. The report analyzes data from four venture capital databases – Thomson Reuters, BioCentury, Elsevier, and Evaluate Pharm – to investigate investor trends, examine investment in specific therapeutic areas and indications, and identify disease areas that might be struggling for early-stage venture Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

BIO Accepting Nominations for its Award Honoring One Outstanding Woman in Industrial Biotech

Nomications

Today, BIO announced that it has officially extended its deadline for the Rosalind Franklin Award for Leadership in Industrial Biotechnology. In its second year, the BIO Rosalind Franklin Award was created to honor an outstanding woman in the field of industrial biotechnology and bioprocessing.  Rosalind Elsie Franklin (25 July 1920 – 16 April 1958) was a British biophysicist and X-ray crystallographer who made critical contributions to the understanding of the fine molecular structures of DNA (deoxyribonucleic acid), Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , ,

Nasdaq Social Bell: Twitter Strategies For Biotechs

Nasdaq Social Bell

Last week at the BIO CEO & Investor Conference in New York City, I had the pleasure of speaking with John Machiz and Brad Smith from Nasdaq at their headquarters in Times Square to discuss the social media activity that happened onsite during the event, what made the discussion of the event online so robust, and what biotech companies can do to increase their visibility on Twitter. View the video below, and get a recap of the Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Deal Structures: More Options for Companies

CEO2013_115x75_Thumbnail copy

By most measures, 2014 was a great year for the biotechnology industry. Venture capital deal values, , licensing values and volume were all up, as were big pharma M&A deals and asset swaps. What do these trends mean for dealmakers in 2015? Answering that question was the task of a panel at the 2015 BIO CEO & Investor Conference, Emerging Trends in Deal Structures. Moderated by Fenwick and West’s Effie Toshav, the panel included: Bruce Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , ,

Ten Years of Therapeutic Venture Capital

vc-blog

What therapeutic areas have received the most funding in private drug companies over the last decade? How much of this has been for new drugs vs drug delivery? How much into biologics vs small molecules? This week, we released a first-of-its-kind, comprehensive report on venture capital trends covering 2004-2013. To investigate investor trends in specific therapeutic areas and level of innovation, we analyzed data from four venture capital databases to create the broadest, most comprehensive Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , ,